Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862277 · ClinicalTrials.gov registry record
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
A clinical trial, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 763
- Enrollment target
NCT00862277 is a clinical trial that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 763 participants.
The verdict
NCT00862277 has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 763 participants
- Enrollment target
Study Summary
To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier
Interventions
- BIOLOGICAL Menactra®
- BIOLOGICAL Menomune®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 763 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00862277
The ClinicalTrials.gov registry entry for NCT00862277 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 763 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Menactra® is the first listed.
NCT00862277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00862277 about?
NCT00862277 is a clinical study titled "Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine". To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier
What is the current status of trial NCT00862277?
This trial is currently completed. The enrollment target is 763 participants. The study started on 2008-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00862277?
The interventions under investigation include: Menactra® (BIOLOGICAL), Menomune® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00862277?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.